Fierce Biotech May 23, 2024
Guardant Health’s blood test designed to help screen the population for hidden cases of colorectal cancer may have taken a step closer to FDA approval.
An independent advisory panel convened by the agency voted in favor of a green light for the company’s Shield test, which is currently under review.
The ultimate objective of the test is to offer people at an average level of cancer risk a more convenient, first-line option when it comes to starting the screening process. While having a colonoscopy once every 10 years remains the gold standard for uncovering tumors and precancerous polyps, today’s screening rates still lag behind national goals.
By detecting the presence of altered tumor cell DNA through a standard blood...
Today's Sponsors
Today's Sponsor